Concord Biotech Ltd successfully completes PPB and NDA inspection

Concord Biotech Limited has announced the successful completion of inspection by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda at Unit-II formulation facility. The inspection took place from June 18, 2026 to June 24, 2026, and was concluded successfully.

The successful completion of PPB and NDA inspection marks a significant milestone in Concord Biotech's global growth journey. This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint.

Shares of Concord Biotech Limited was last trading in BSE at Rs. 1288.65 as compared to the previous close of Rs. 1318.95. The total number of shares traded during the day was 10486 in over 900 trades.

The stock hit an intraday high of Rs. 1331.25 and intraday low of 1283.50. The net turnover during the day was Rs. 13612792.00.

Source : Equity Bulls

Keywords

ConcordBiotech Pharmaceuticals INE338H01029 PPB Kenya NDA Uganda Inspection FormulationFacility Unit2